Orlando, FL -- (SBWIRE) -- 10/01/2013 -- Hot Stock Profits provides investors and traders with valuable trading tools and content as well as micro-cap stock alerts via eMail and text messages. To Join Our Text Message Alerts Service Just Text The Word Stocks To 555888 From Your Cell Phone. Our Focus Today Is On EnteroMedics Inc (NASDAQ:ETRM), Array Biopharma Inc (NASDAQ:ARRY).
EnteroMedics Inc (NASDAQ:ETRM) stock jumped 2.05% to $1.25. The company announced that Greg S. Lea, EnteroMedics' Chief Financial Officer and Chief Operating Officer, was scheduled to present at the Craig-Hallum 4th Annual Alpha Select Conference on September 26, 2013 at 9:10 am Eastern Time at the Convene Conference Center in New York, NY. Mr. Lea will provide an overview of the Company and its VBLOC® vagal blocking therapy development and commercialization program.
Additionally, the company on Sept. 24 announced that the Company has received a formal response, a standard component of the PMA process, from the Food and Drug Administration (FDA) with regard to its Premarket Approval Application (PMA) for approval of the Maestro Rechargeable System as a treatment for obesity. The response contains follow-up questions related to the application pertaining primarily to device testing and clinical data, including training programs for users and a post approval study. The Company anticipates responding to the FDA's questions within the coming weeks.
Are investors worried about the recent updates with ETRM? Find out with a free trend analysis HERE
Array Biopharma Inc (NASDAQ:ARRY) shares jumped 1.97% to $6.22. The company announced that its Chief Executive Officer, Ron Squarer, will speak at the NewsMakers in the Biotech Industry Conference on Friday, September 27, 2013 at 10:30 a.m. Eastern Time
Additionally, the company on August 7 said it would cut 20 percent of its workforce as Amgen Inc plans to end an agreement to develop and market Array's drug to treat Type 2 diabetes. The company said it would record a one-time restructuring charge of $2.7 million in the first quarter of fiscal 2014. The company said it would have 200 employees after cutting 50 jobs. Most of the job cuts will be in the company's drug discovery business.
Is ARRY going to continue its rally or drop like a rock? Find out with a free trend analysis HERE
Join Our Mobile SMS Alerts By Texting Stocks To 555888
HotStockProfits.com continuously monitors and scans the markets for day trading and swing trading signals on NASDAQ, NYSE, AMEX, OTCBB and Pink Sheet companies for its free e-newsletter subscribers.
HotStockProfits.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit HotStockProfits.com website, for complete risks and disclosures.
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)